Avacta Group, a technology company providing analytical and diagnostics solutions to the life sciences and healthcare sectors, has announced its interim results for the period ended 31 January 2012.
Highlights include a 72 per cent rise in revenue to £1.72m and a strong balance sheet with £5.81m in cash.
Losses per share improved to 0.02p and there was a reduction in operating loss before amortisation and share-based payment charges to £0.39m.
Furthermore, the £4.87m was raised to fully fund the group to accelerate growth through investment in the AX.1 test menu, new technology products and the new affinity reagents platform.
